Primary Neuroendocrine Tumor of the Scrotum: An Uncommon Site for a Rare Tumor

J Investig Med High Impact Case Rep. 2021 Jan-Dec:9:23247096211008717. doi: 10.1177/23247096211008717.

Abstract

Neuroendocrine tumors (NETs) are a heterogeneous group of tumors developing from neural crest cells, with numerous sites of origin, commonly the gastrointestinal and genitourinary tracts. NETs of the genitourinary tract are more common in women. Small cell carcinoma of the prostate or testicular carcinoid are the NETs in male. In this article, we present a rare case of NET of the scrotum. Our patient was a 47-year-old male with a history of complicated pilonidal cysts resulting in chronic scrotal wounds. Biopsy of a large nonhealing scrotal wound revealed a high-grade neuroendocrine carcinoma with features most suggestive of small cell carcinoma. Presenting with advanced disease at diagnosis, he was started on systemic therapy and unfortunately progressed through multiple lines of treatment, including CAPTEM (capecitabine and temozolomide). Unfortunately, due to multiple logistical reasons, the patient was unable to receive the then off-label immunotherapy based on DART (Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors) trial. He, unfortunately, succumbed to his disease within months of diagnosis.

Keywords: neuroendocrine tumor; scrotal carcinoma; scrotal malignancy.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Capecitabine / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuroendocrine Tumors* / diagnosis
  • Neuroendocrine Tumors* / drug therapy
  • Scrotum*
  • Temozolomide / therapeutic use

Substances

  • Capecitabine
  • Temozolomide